GridAI Technologies Positions Itself at the Crossroads of AI and Power Management

GridAI Technologies (NASDAQ: GRDX) is advancing its strategy to address the surging energy demands of AI data centers by acquiring Grid AI, Inc. and appointing a new CEO with deep industry experience.

Bay Area Metrowire Staff
••Technology
GridAI Technologies Positions Itself at the Crossroads of AI and Power Management

GridAI Technologies (NASDAQ: GRDX) is making strategic moves to capitalize on the growing intersection of artificial intelligence and energy infrastructure. Following its acquisition of Grid AI, Inc., the company is focusing on developing next-generation power management software tailored for hyperscale AI data centers. The announcement comes as the AI data center market is projected to reach $1 trillion by 2030, intensifying the need for intelligent energy orchestration solutions.

GridAI Technologies recently named Marshall Chapin as the CEO of its GridAI, Inc. subsidiary. Chapin brings decades of leadership experience in grid optimization, energy transition, and distributed energy sectors. Since March 2025, he has served as the Interim CEO of Amp X, an AI-driven grid-edge platform that is also a GridAI subsidiary. His appointment underscores the company's commitment to deploying a state-of-the-art orchestration engine capable of managing the power and flexibility demands of the massive AI data center market.

The company's AI-driven energy orchestration platform coordinates distributed energy resources across multiple scales, addressing critical challenges in power management for data centers. As AI workloads continue to expand, the need for efficient and reliable power distribution becomes paramount. GridAI's software aims to optimize energy usage, reduce costs, and support the integration of renewable energy sources.

GridAI Technologies (formerly Entero Therapeutics Inc.) is a publicly listed diversified technology and life sciences company on the Nasdaq. In addition to its GridAI operations, the company continues to advance its late clinical-stage biopharmaceutical program focused on developing targeted, non-systemic therapies for gastrointestinal diseases. This dual focus allows the company to pursue opportunities in both the tech and life sciences sectors.

For more insights into the company's strategy, the full article can be accessed at https://ibn.fm/87zSn. The company also notes that forward-looking statements involve risks and uncertainties, as detailed in its filings with the SEC. Investors are encouraged to review the full terms of use and disclaimers available at http://IBN.fm/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration